ABSTRACT
INTRODUCTION
Thiazolidinediones (TZDs) are a class of insulin-sensitizing agents commonly used to treat patients with Type II Diabetes Mellitus. This class of drugs acts by binding the peroxisome proliferator-activated receptor gamma (PPAR-γ ) nuclear receptor (Olefsky and Saltiel, 2000) , thereby modifying transcription of key glucoregulatory and lipid regulatory genes (Suzuki et al., 2000; Albrektsen et al., 2002) . Several individual downstream targets of PPAR-γ have recently been identified and confirmed by RT-PCR, but the mechanism of insulin sensitization is still poorly understood. A fundamental understanding of the gene transcription events leading to the anti-diabetic action of TZDs would greatly enhance our understanding of insulin action, insulin resistance and enable new, more focused efforts at drug discovery. To tackle this problem, we treated differentiated 3T3-L1 adipocytes with three different TZDs (Pioglitazone, Rosiglitazone and Troglitazone) and followed up with microarray analyses of RNA.
Microarrays have revolutionized modern cell biology by opening a broader window to the influence of physiological perturbations on gene regulation. Although a variety of statistical methods are available and are used to analyze microarray data, the field of microarray statistics is still in its infancy and is being actively developed. At the present time, array statistics can be subdivided into three principal levels: (1) providing summary statistics that indicate the degree of gene expression of each array feature from microscope imaging data, (2) deducing the measurement uncertainty between summary statistics of multiple experimental replicates to determine which genes are differentially expressed and (3) determining patterns in gene expression in several tissues, or under various perturbations. For the first class of microarray statistics, the methods for summarizing gene expression are quite well-developed, and have been much improved by the work of Wong and others (Shadt et al., 2000) . The latter two classes of array statistics unfortunately still lag behind, and are a fundamental limitation to precise, reproducible interpretations of array data.
Measurement variance is an indication of the reproducibility of several measurements given the same experimental conditions. A number of potential sources of variability exist, which lie beyond the control of the experimenter, and many of these can influence individual genes differently. It has been widely observed that the degree of measurement uncertainty is dependent on the level of gene expression. In many cases, the variance decreases as a fraction of the total signal as the expression level increases. Among the sources of error that are independent of gene expression are the random noise introduced by the equipment used to gather image data and variability in the quality of fluorescence. In addition, the strength of hybridization and the absolute amount of RNA harvested from the sample are examples of factors that influence variance in an expression-level-dependent fashion. Biological variability, the changes in gene expression that are variable between controlled measurements, may contribute to both classes of variance. All these factors affect the level of reproducibility. In order to determine whether a particular gene measured on an array is differentially expressed between two physiological conditions then, it is necessary to account for uncontrollable sources of variation.
A fold-change cutoff remains the de facto standard for this level of array analysis, but several recent articles assert the need for more updated analytical methods (Miles, 2001 ). Fold-change approaches qualitatively give a fair level of reproducibility, but are plagued by the lack of a solid statistical foundation, and are unable to handle expression-dependent variability. To perform this kind of analysis, practitioners compute the ratio of gene expression between two treatment conditions, where one is a 'treated' and the other is a 'control' experimental condition. When the ratio exceeds an arbitrary threshold, often a 2-fold increase or a 0.5-fold decrease, the gene associated with the array feature is considered to be 'differentially expressed'. This method has been improved by the introduction of a minimum-expression cutoff to account for the increased fractional variability at lowexpression levels. Despite these improvements, this approach is still rather arbitrary because the best cutoffs are difficult to determine a priori, and it is difficult to correlate these cutoffs with traditional concepts of statistical significance. Several new methods have been developed to address these limitations.
Among the most popular advanced methods for this second tier of analysis currently include Significance Analysis of Microarrays (SAM) (Tusher et al., 2001) and Cyber-T . SAM utilizes a non-parametric bootstrap technique to estimate the degree of variability for each feature of the array. Cyber-T, in contrast, relies on a Bayesian modification of a traditional t-test. In order to better assess the uncertainty, Cyber-T examines the variance of features in a gene expression window near the sample mean of the feature of interest, and uses these as 'pseudo-replicates'. Both methods are substantial improvements over fold-change approaches as they can ascertain the significance level of observed changes in gene expression.
It is our opinion that this tier of analysis can be improved further by more precisely modeling the relationship between variance and gene expression level. By incorporating this model into statistical analysis, the accuracy of calls for 'differentially expressed' genes should be substantially increased. Noting that the number of replicates of microarray experiments tends to be small, often numbering between two and four per treatment condition, it is likely that the variance estimates derived from a global model will likely be more accurate than estimates obtained from individual features alone. We therefore choose to apply a global variance model related to that proposed by Rocke and Durbin (2001) to approximate the relationship. Given the parameterized relationship between variance and mean expression, we apply a Bayesian hierarchical model to compute a likely prior density for the 'true mean' expression level of each feature on the array, and compute the corresponding posterior density after observation of each replicate. The net effect is the conversion of a few point measurements into an easily interpretable likelihood density for the 'true mean' expression of each feature. This can be used to answer a wide assortment of analytical questions, including whether a gene is differentially expressed between two treatment conditions.
METHODS AND STATISTICAL FRAMEWORK
Only a handful of assumptions are needed to develop a fairly rigorous statistical method for the analysis of microarray data. It is assumed here that there is a 'true' expression level for each feature in the array, designated µ i . Each measurement of a particular feature is considered to be a sampling from a distribution centered about µ i , and whose variance is σ 2 i . We also assume that the likelihood of any measurement from this distribution is approximately normal. So far, these assumptions are typical of many statistical tests, including the t-test. We also assume that the variance can be expressed as a deterministic function of µ i . In other words, there is no uncertainty in the amount of variance for a feature, if both (1) the feature's 'true' expression level is known and (2) the relationship between and 'true' expression and variance is known. A last assumption used in this method is that in the absence of prior observations, the prior knowledge about the 'true' expression, µ i , is given by the local distribution of sample means. If additional prior knowledge is available, these data can alternatively be used to construct prior densities for µ i .
The above assumptions are encapsulated by a Bayesian statistical model (Fig. 1) . By applying Bayes' rule to a given prior density, we can narrow the posterior density for each µ i after observing several replicates of microarray data. The model that we choose belongs to the exponential conjugate family devised by Morris (1983) . The likelihood function for the univariate exponential family can be expressed as
where θ is the unknown parameter and x is a single measurement. For the normal density with known variance,
where the variance of the normal density is represented as σ 2 . Applied directly to the microarray problem, the unknown parameter θ is our 'true mean', µ i . Given a conjugate prior of the form,
The conjugate posterior is
where α, β are arbitrary prior parameters and the corresponding conjugate posterior parameters are given by
and m is the number of array replicates.
We can re-express the posterior in a more familiar form. Rearranging terms and completing the square, the conjugate posterior becomes:
Therefore, the conjugate posterior is a normal density with
and
Conjugate families are useful in general because of their ability to simplify computations, but this choice has several valuable properties. In this model, the posterior density for the unknown parameter θ is normal. Normal random variables are easily summed, and therefore testing the equality of µ i between two experimental conditions becomes a simple Z-test. This test can be rapidly performed by evaluating an error function. Furthermore, since the ratio of two normal random variables is a Cauchy random variable, posterior densities for fold changes between experimental conditions can be easily assigned. This may be useful in determining the posterior density for a fold-change statistic.
Variance model
Measurements of microarray data are modeled with a two-component global variance model as described previously by Rocke and Durbin (2001) . In their model, the variance is decomposed into expression-dependent variance, σ 2 η , and expression-independent variance, σ 2 ε , which are assumed to be constant parameters for a given microarray experiment. A similar model was also used by Ideker et al. (2000) for determining the significance of gene expression changes in two-color microarrays. It can easily be shown that the relationship between variance and true expression level can be written as
and when σ is small compared to µ, the log-transformed variance is related to the non-transformed variance by
and thus,
where A is the expression-dependent variance, and B is expression-independent variance for the random variable X (Appendix). Furthermore, if X is normal, then in the limit that σ is very small compared to µ, log(X) will also be approximately normal. Given these expressions for variance, there are several methods that we can use to estimate the components of variance directly from microarray data in either non-transformed or log-transformed coordinates. One approach is to use leastsquares regression to approximate the curve that best-fits the observed mean squared deviations (MSDs) at each expression level. The MSD are the maximum-likelihood estimator for the variance of each array feature. Ideally, we would square the differences between the measurements and µ i , but the MSD uses the sample mean, m i , as a surrogate. We have observed empirically that this method gives better results when performed in log-transformed rather than in non-transformed coordinates. A second approach is to use a Markov chain Monte Carlo (MCMC) method to compute estimates for the unknown parameters, A and B. We simulate the likelihood function for all of the measurements X, and use this to compute the mean and variance of the posterior densities. The variance gives us an indication of convergence of the MCMC simulation. The likelihood function for each measurement is a normal likelihood given by
where i indexes each array feature and j indexes each replicate measurement. As in the case of least-squares regression, µ i is again unknown, so we use the sample mean, m i , as a surrogate. While it would be ideal to integrate out µ i , analytical integration of this equation is impractical.
According to the variance model, the sample mean, m i , becomes an increasingly inaccurate estimator of µ i at low expression levels, where fractional variance is largest. This causes the MSD to dramatically underestimate the true variability. Qualitatively, we can understand this by noticing that µ i does not necessarily lie at the center of observed measurements, but m i always does. Since this can impair the accuracy of both approaches for estimating A and B, it becomes necessary to draw an expression-level cutoff for the purposes of estimating the unknown parameters. Only measurements whose sample means reside above the cutoff are used. The use of a cutoff is substantial departure from previous attempts to estimate the parameters of the two-component variance model. The issue of where a reasonable cutoff should reside will be addressed later, but once parameter estimates are available, they apply to all of the features on the array, regardless of where the cutoff is ultimately drawn.
Prior density for µ i
The prior density describes the relative likelihood that 'true' gene expression, µ i , is any particular value, before any measurements are observed. It summarizes our prior knowledge about µ i . Since we are using the exponential conjugate model, any prior of the form
could theoretically be used. If previous measurements are available, then the corresponding posterior densities can be parameterized by the above equation and used as a prior. In most cases though, no obvious prior exists. One reasonable choice then, is to compute a prior for µ i by simulating the likelihood density for prior parameters with MCMC. To do this, we consider each gene expression measurement as a sampling from the hierarchical model whose prior is parameterized by an exponential distribution. We can then find an estimate of the unknown hyperparameter after observing all of the measurements. It is by systematically estimating the hyperparameter, λ, rather than arbitrarily choosing a value, that we make this model truly hierarchical. The exponential prior can be expressed as
An added complication arises because the likelihood function of our Bayesian model assumes that variance is constant, which is not globally true given our variance model. However, locally within a given 'expression region', variances are relatively constant. It is therefore possible to compute the parameters of an exponential prior in the vicinity of each expression level. The likelihood of observing a set of data is described by
where the data-likelihood function is
and the prior density for µ i is
In these equations, X ij represents the measurements of features found in the expression region, i indexes each feature, j indexes each of the r replicates, [a, b] gives the boundaries of the local vicinity and σ 2 is the corresponding variance. The method we devised to perform segmentation of the array features may be found in the Appendix. Integrating out µ i , we find
where
where r is the number of array replicates, a and b are the segment boundaries, andx i and s 2 i are the mean and sample variance of the i-th feature, respectively.
Posterior density for µ i
The posterior density describes our knowledge about the likely values for the true gene expression, µ i , after observing data. In our Bayesian model, this density is normal, and the parameters of the posterior are readily interpreted. They are
The mean of the posterior is just the sample mean modified by a 'posterior shift', and the variance of the posterior is simply the experimental variance scaled down by the number of replicates, m. These parameters can be understood qualitatively.
As the slope of the prior, −λ i , grows more negative, the posterior density is shifted further to the left. With a greater λ i , there are many more features on the array whose 'true mean' expression lies to the left, that it is more likely that µ i for the current feature also lies to the left. This change is mediated by the magnitude of uncertainty in our measurement of the sample mean, σ 2 /m. As the number of replicates grows, the uncertainty in 'true' gene expression decreases, and the magnitude of the posterior shift also decreases.
Statistical tests
One of the most common tasks in the analysis of microarray data is to determine what features are differentially expressed between two experimental conditions. Recognizing that the posterior densities for µ i in each treatment are normal, the summary statistic
The superscripts e and c designate the posteriors of the experimental and control treatments, respectively. Thus, we can simply test the null hypothesis
to determine whether the i-th feature is differentially expressed. When the difference between the posterior densities of µ i for two treatments is sufficiently large, then the change in expression is considered to be 'significant'. This is qualitatively similar to the t-test, as well as traditional fold-change approaches to array analysis. Unlike a t-test though, where the observed means are compared to the observed sample variance, we instead compute the likelihood that the statistic Z overlaps with 0. The corresponding Z-score depends on the uncertainty in our knowledge of µ i , and not on any particular observation of sample variance. In order to provide a meaningful indication of statistical significance that can readily be understood by the biological sciences community, we define a P -value as
where f (z i ) is the density function for Z i . It is worthwhile to note that the P -value of a t-test is defined in a similar manner. In addition, we define statistically significant differential expression of the i-th feature as fulfillment of the inequality
where α is the Bonferroni-corrected significance threshold as described in Baldi and Long (2001) . Since the number of features on each array tends to be large, it is necessary to correct the number of statistical tests. To achieve an experiment-wide false-positive rate of α Bonf ,
where N is the number of features on the array. Another useful statistics easily obtained from this model is the posterior density of a fold-change in expression level. Since the ratio of normal densities is Cauchy, the fold-change statistics is the Cauchy density given by 
Implementation
The statistical methods and parameter estimation procedures described in this paper are implemented in a collection of command-line JAVA tools using standard objectoriented design techniques. This collection of tools, known as VAMPIRE (Variance-Modeled Posterior Inference with Regional Exponentials), handles estimation of the variance model parameters, calculates the maximum-likelihood estimates for the exponential prior, computes the posterior densities for each feature in the array, and computes P -values for comparison of multiple experimental treatments to a set of controls. The MCMC framework used in VAMPIRE is a freely available JAVA package known as Hydra, written by Gregory Warnes. In all cases, we applied the CustomMetropolisHastingsSampler for simulation with a NormalMetropolisComponentProposal suggesting potential states. To estimate variance parameters, proposal states were generated for log(A) and log(B) with variances of 0.5. For the hyperparameter, we used (1) in log-transformed coordinates, a start state of 1.0 and variance of 1.0 propose new states and (2) in non-transformed coordinates, a start state of 0.0 and the proposal had a variance of 10 −5 . Additionally, the open source library COLT is used for statistical computations and random number generation.
Analysis with SAM and Cyber-T
Both Cyber-T and SAM were used to complement the analysis performed by VAMPIRE, and to demonstrate the relative effectiveness of each method. Cyber-T was performed with the default parameters provided on the website with the exception of setting the 'confidence' in the Bayesian estimate, ν, to the suggested value, 10. 'Significant' features were defined as the subset of array features whose P -values resided below α = 2.00 × 10 −6 (a two-sided test with α Bonf = 0.05). Similarly, we used the two-class, unpaired test in SAM while adjusting the parameter to achieve a median fraction of false significant genes of 0.05.
ARRAY ANALYSIS OF 3T3-L1 ADIPOCYTES
The previously described statistical methods were used to examine gene expression changes in 3T3-L1 murine adipocytes in response to treatment with several different TZDs.
Cell Culture 3T3-L1 fibroblasts were grown in DMEM-high glucose (25 mM glucose, 1.8 mM CaCl 2 ) medium containing 10% calf serum. Two days post-confluency fibroblasts were differentiated into adipocytes in DMEM-high glucose containing 1 µg/ml insulin, 0.1 µg/ml dexamethasone and 112 µg/ml isobutylmethylxanthine to the medium. The differentiation medium was removed after 4 days and replaced with DMEM-high glucose containing 10% fetal calf serum, Glutamax and 1% penicillin-streptomycin. The medium was changed every third day.
RNA preparation and microarray analysis Twelve days postdifferentiation, 3T3-L1 adipocytes were incubated for 24 h with one of the following TZD or with vehicle (0.1% DMSO): 20 µM troglitazone, 20 µM pioglitazone, 1 µM rosiglitazone. After treatment, total RNA was prepared from cells using Trizol (Invitrogen). Double-stranded cDNA was synthesized with the SuperScript Choice system (Invitrogen) using a T7-(dT) 24 oligomer (Ambion) and the RNA from each treatment condition. Biotin-labeled probes from the cDNAs were subsequently obtained by in vitro transcription using the BioArray High Yield RNA transcript Labeling Kit (Enzo). The probes were then hybridized to U74Aver2 Affymetrix GeneChips. The GeneChip microarrays were hybridized for 16 h at 45 • C and 60 rpm in a rotisserie box. GeneChips were processed further using the standard Affymetrix protocols for eukaryotic GeneChips. Average difference scores for each gene feature were determined using the scanned GeneChip image and Affymetrix MAS 5.0 software. The microarray data described in this study has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database, and can be accessed at http://www.ncbi.nlm.nih.gov/geo (accession no. GSE1458).
RESULTS

Variance model parameter estimation
Accurate estimation of the parameters of the variance model is critical for the interpretation of observed changes in gene expression. In order to account for the poor accuracy of m i as an estimator of µ i at low expression levels, we introduced the concept of an expression-level cutoff. Only when the sample mean of a particular microarray feature lies above the cutoff are the measurements from this feature used in parameter estimation. We expect that cutoffs set too low would give poor variance estimates. On the other hand, we expect that cutoffs set too high would cause parameter estimates to become increasingly unstable. Between these two extremes is where a reasonable cutoff should lie. Two methods were employed to estimate variance parameters in each of the 3T3-L1 treatment conditions, and both give comparable results across a broad spectrum of expression-level cutoffs.
Similar behavior is observed for all of the treatment conditions with respect to the choice of expression-level cutoff. Estimates for expression-dependent variance, A, decrease with expression level cutoff until estimates by both methods level off. In contrast, estimates of expression-level independent variance, B, gradually increase as the cutoff increases, reach a plateau, and then become increasingly instable. When cutoffs are drawn at even higher levels, expression-dependent variance dominates until expression-independent variance is virtually undetectable by either method of estimation.
The plateau represents a broad region where the parameter estimates are stable against the cutoff choice. Within this region lie the most reliable point estimates for A and B. When no cutoff is used, we anticipated that variance estimates could be rather inaccurate since the MSD tend to underestimate the true variability of low-expression features. Since expressionindependent variance typically dominates measurements of low-expression features, it is clear that the total variance for these features is drastically underestimated when no cutoff is used. For high-expression features, the accuracy of MSD is not as much of a problem, and the model compensates for the differential behavior of MSD by overestimating A and underestimating B. The opposing behavior between A and B continues as expression level cutoffs increase, until a plateau is reached.
In order to choose the best cutoff then, it is necessary to choose a point in the region where estimates of A and B plateau, prior to becoming unstable. MCMC, being a more robust statistical method, is much less sensitive to the choice of cutoff than the regression approach, and gives stable estimates for a broader range of cutoffs. An additional advantage is that its estimates are bound to physically meaningful values, where regression can potentially give negative estimates of variance parameters. It is therefore reasonable to choose MCMC as the final estimator of the parameters of variance given a choice of a cutoff. The benefits of MCMC simulation unfortunately come with increased computational cost. In order to strike a balance between accuracy and computation time, the automated cutoff choice in VAMPIRE uses regression to 'test' a spectrum of potential cutoffs. The automated cutoff is then determined as the mean of the broadest range of cutoffs for which there is <10% variation in √ B, the expression-independent error. The cutoff choice is then supplied to the MCMC simulator for final parameter estimation. With this cutoff choice, the estimated variance is essentially the same across each of the treatment sets (Fig. 2) . Illustrative of this point, when the parameter estimates for the control treatment are applied in place of the correct estimates for any of the TZD treatments, the number and identity of differentially expressed genes only changes by 10-15% (data not shown). This variation is smaller than that observed between the differentially expressed genes obtained from each of the TZD treatments.
In log-transformed coordinates, both methods of parameter estimation provide qualitatively good fits with MSD beyond the cutoff where they are trained (Fig. 3) . Below this cutoff however, MCMC-simulated parameter estimates appear to fit the MSD better than regression estimates. This is particularly noticeable in non-transformed coordinates. There are a couple of potential reasons for the superior quality of MCMC-simulated parameters. Least-squares regression is performed in log-transformed coordinates rather than the non-transformed coordinates that MCMC uses. Since the log-transformed equation of variance (12) is inherently inaccurate at low expression levels, this introduces some error into the regression parameter estimates. Applying the regression approach in non-transformed coordinates is even worse; it frequently gives negative variance parameters. This is because this method is a purely mathematical approach, and is not constrained to physically meaningful values. Since the curve is non-linear, least-squares regression is not expected to give the maximum-likelihood estimate of the parameters. Instead, as it tries to minimize square distances, it fits steep-sloped portions of the curve more tightly than milder-sloped portions, giving biased estimates. MCMC simulation is not hindered by these limitations.
These results also demonstrate the behavior of MSD at very low expression levels, where MCMC-derived estimates of variance no longer fit the observed MSD. As mentioned previously, this is a limitation of MSD as an estimator of σ 2 i , because of the use of m i as a surrogate for µ i . The downward bias introduced by employing this surrogate can be understood by examining the behavior of MSD. Given a mean expression x , there is a fundamental limit to the maximum value that the mean square deviation can attain. This upper bound is given by
where n is the number of replicate measurements (Appendix). When the variance is large compared to the signal, as is the case at low expression levels, MSD are depressed (Fig. 3b) , and should not be used to estimate variance. It is worthwhile to note that the use of a parameterized variance model is the major difference between current global and local variance model approaches. When using a global model, it is assumed that there is a strong correlation between variance and each independent variable, whereas a local model makes no such assumptions. It is clear that by plotting MSD against sample means that such a relationship exists, and furthermore can be well parameterized by the model we have chosen. When the sample sizes are small, the global model of variance has several advantages over the local one. In Cyber-T, SAM and other methods that do not take advantage of modeling variance across the array, some variant of MSD is used as the indicator of measurement uncertainty. This can be remarkably inaccurate. MSD, for the most part, can be considered as independent samplings from a density centered about the 'true' variance, approximated by the global model. When replicate numbers are low, these samplings may dramatically underestimate or overestimate the underlying variance. At low-expression levels, these methods will theoretically detect too many genes to be differentially expressed as the variance is systematically underestimated. In most cases though, since the replicate number is taken into account, these methods will be overly restrictive for most array features, and as a whole, very few gene expression changes will be detected as statistically significant, due to the inherent uncertainty in small sample sizes. The variance estimates for each of the treatment sets were very similar. This result is not altogether surprising because the sources of experiment-to-experiment variability are very similar. The same methods were used to derive cell lines, treat with TZD or DMSO, and the same protocol was used to purify mRNA, hybridize and measure signals from each of the chips. The variance parameter estimates then, can be a useful indicator of experimental consistency. A dramatic increase in variance between experimental treatments could either indicate a fundamental impact of treatment on biological variability, or simply a flaw in the design or execution of the experiments themselves.
Prior parameter estimation and posterior shift
In order to find a local prior at each expression level, array features are first segmented into several non-overlapping expression regions. Within each region, a local exponential density is used to approximate the observed density of sample means (Fig. 4) . As this exponential is parameterized by a single hyperparameter, λ, a probable prior can be computed by MCMC simulation of the marginal-likelihood function (15). A point estimate for λ is thus computed for each expression region. As the curvature of the variance function though, and since there are far fewer array features that exhibit high expression levels, it is necessary to model high expression levels in log-transformed coordinates. Otherwise, there are simply too few features per region to obtain meaningful point estimates. In the log-transformed coordinate system, variance stabilizes as expression-levels increase, allowing for broader ranges of expression levels to be included in each region. With this change, it is then possible to estimate the hyperparameter λ for an exponential prior in each high-expression region.
Although only a single-point estimate of λ is computed for each expression region, there are a number of ways to extrapolate λ i for each feature (Fig. 5) . The most straightforward approach is to determine which region the ith feature belongs to, and set λ i equal to the corresponding estimate. With this method, the 'shift' in the mean of the posterior becomes a discontinuous function. These discontinuities are likely an artifact of regional segmentation, and do not represent any fundamental behavior of the data. In order to adjust for this, a second approach was taken to extrapolate λ i . The 'posterior shift' from the latter term of (21), was computed at the mean of each expression region, and we applied piecewise continuous finite elements to approximate the best-fit line between these points. In addition, we constrained the finite elements to 2 fewer degrees of freedom than the number of data points we had to approximate with, and weighted each data point by the inverse variance of the posterior density for λ. This allowed the finite elements to fit the posterior shifts related to more accurate estimates of λ more tightly, while allowing freedom around vague estimates. This more sophisticated method of interpolation smoothes out the discontinuities between expression regions, but at a slightly greater computational cost. Surprisingly, the number of significant gene expression changes did not change by more than 5% when either method was applied, and the identity of significant changes was essentially the same (data not shown). In our data, this may be because the posterior shift was small compared to measured expression levels. Therefore, although theoretically superior, finite element extrapolation of λ i may not always be necessary to obtain useful results. In other datasets however, this prior may have a more marked effect. Therefore, both methods have been implemented in the VAMPIRE package.
Posterior inference
Once a local prior is calculated, and the posterior density for the 'true mean' expression is computed for each feature on the array, it becomes possible to make inferences on whether observed changes in gene expression are statistically significant. Based on the posterior densities for µ i , a P -value for each array feature was computed, comparing each treatment to the control. As expected, when we analyzed the 3T3-L1 data, only a subset of the largest fold changes was determined to be statistically significant. The fold-change threshold for significance was much higher for low-expression features than for high-expression features. This dependence of the significance threshold on expression level mirrors the behavior of the log-transformed equation of variance (12).
The strong correspondence between our global variance modeling approach and traditional fold-change approaches is clearly evident (Fig. 6) . All of the features with statistically significant changes in gene expression can also be found by applying a standard 2-fold/0.5-fold cutoff. Unfortunately, if we chose to use a fold-change cutoff alone, we would find so many spurious results at low expression levels that they would vastly outnumber those that are truly significant. Since expression-independent variance dominates at low-expression levels, and can constitute a large fraction of the observed signal, dramatic fold-changes in gene expression can often occur by random chance alone. To address this concern, many researchers also institute minimal expressioncutoffs, but optimal thresholds for maximizing sensitivity and specificity are difficult to determine a priori. Furthermore, the level of statistical significance of the chosen threshold is difficult to determine. Variance-modeled posterior inference inherently addresses these issues. Once an experiment-wide false-positive rate is specified, the fold-change thresholds required for statistical significance are implicitly computed across all expression levels. There is little need for additional filtering of low-intensity measurements prior to analysis.
We employed two additional methods for the analysis of our 3T3-L1 microarray data. Both SAM, which uses a nonparametric bootstrap method, and Cyber-T, which applies Bayesian statistics for a modified t-test, have become popular tools. The first set of analysis was performed by pooling TZD-treated data into a single 'treated' data set (n = 8), and compared to DMSO controls (n = 3). With an experimentwide false-positive rate of 0.05 for Cyber-T and VAMPIRE, and a false discovery rate of 0.05 for SAM, all three methods showed substantial overlap in the sets of genes considered to be differentially expressed (Fig. 7) . Nearly three out of four genes detected by Cyber-T (default parameters, ν = 10) were also detected by VAMPIRE, while over half of the 'significant' features in SAM were also 'significant' in VAMPIRE. The considerable overlap is strongly suggestive that the genes detected by each of these methods are indeed differentially expressed. Moreover, since the number of detected features are very similar, it is likely that all three methods share a comparable level of sensitivity under these conditions.
At an estimated experiment-wide false-positive rate of 0.05, each analysis tool also produced a set of genes that were not detected by either of the other methods. Among the 23 genes that were only identified by VAMPIRE, 4 had known function in glucose metabolism, lipid metabolism Gene SAM Cyber-T VAMPIRE Statistics P R T X P R T X P R T X C P R T X Z37107 Ephx2 U U 2.6 2.7 2.5 1174 2.5 ± 0.6 2.1 ± 0.6 2.5 ± 1.0 2.4 ± 0.6 AF006688 Acox1 U U 2.5 2.7 2.6 965 2.5 ± 0.7 2.3 ± 0.5 2.4 ± 0.9 2.5 ± 0.6 M61737 Fsp27 U U 2.5 2.2 10771 2.5 ± 0.4 2.3 ± 0.5 2.0 ± 0.7 2.3 ± 0.4 AW122615 -U U U U 2.0 8188 1.8 ± 0.3 2.1 ± 0.1 1.8 ± 0.5 1.9 ± 0.2 M80206 Pvrl2 U U U 2.1 787 1.7 ± 0.2 1.9 ± 0.3 2.1 ± 0.5 2.0 ± 0.3 AI326963 -U U U 2.1 2134 2.2 ± 0.1 2.1 ± 0.2 1.8 ± 0.6 2.1 ± 0.2 AB017112 Slc25a20 U U 2.2 637 2.0 ± 0.4 2.3 ± 0.5 1.7 ± 0.6 2.1 ± 0.4 AA755260 Dp1l1 U U 2.2 2387 1.9 ± 0.2 2.4 ± 0.3 1.9 ± 0.6 2.2 ± 0.3 AA797604 Angptl4 U U 2.2 2547 2.3 ± 0.4 2.3 ± 0.4 2.1 ± 0.7 2.2 ± 0.4 AW125480 1620401E04Rik U U U 5.5 5.8 9.3 7.1 597 5.8 ± 2.2 6.0 ± 2.4 9.2 ± 4.9 7.3 ± 3.5 AJ001418 Pdk4 U U 3.6 3.2 4.3 3.7 810 3.4 ± 1.0 3.0 ± 1.3 3.8 ± 1.5 3.5 ± 1.1 M14044 Anxa2 U U 3.2 3.8 3.7 3.6 4290 3.4 ± 1.0 4.2 ± 1.5 3.8 ± 1.8 3.9 ± 1.3 AW012588 MGC29978 U U 3.9 3.8 3.8 3.8 2079 4.3 ± 1.4 4.2 ± 1.8 4.0 ± 2.1 4.2 ± 1.6 U48403 Gyk U 4.0 4.8 3.4 4.1 444 4.0 ± 1.1 4.7 ± 1.7 3.3 ± 1.7 4.0 ± 1.5 M93275 Adfp U 2.7 2.9 2.5 8683 2.8 ± 0.8 2.0 ± 0.5 2.7 ± 1.3 2.6 ± 0.9 AI324801 Cbr3 U 2.6 2.7 2.6 1756 2.7 ± 0.5 2.3 ± 0.8 2.6 ± 1.1 2.6 ± 0.7 AF007267 Pmm1 U 5.3 5.8 4.7 367 7.8 ± 4.5 4.5 ± 2.6 7.9 ± 4.9 6.7 ± 4.1 U08439 Cox6a2 U U 2.8 2.4 759 2.2 ± 0.4 2.1 ± 0.4 2.4 ± 0.8 2.3 ± 0.4 D26107 Pvrl2 U 2.6 2.5 712 2.3 ± 0.9 2.6 ± 0.8 2.5 ± 1.2 2.5 ± 0.8 AI841389 -U 3.2 2.7 7414 2.1 ± 0.2 2.6 ± 0.5 2.9 ± 1.1 2.7 ± 0.7 M22998 Slc2a1 U 4.1 3.1 412 2.7 ± 1.5 2.7 ± 1.1 3.7 ± 2.2 3.3 ± 1.7 AA871791 1300003D03Rik U 1.9 2327 2.1 ± 0.3 2.0 ± 0.2 1.5 ± 0.4 1.9 ± 0.3 AI838015 Prss15 U 1.9 3423 1.8 ± 0.4 1.8 ± 0.5 2.2 ± 0.8 2.0 ± 0.6 AW047688 0610039N19Rik U 2.1 2931 2.5 ± 1.0 2.5 ± 1.2 2.4 ± 1.2 2.5 ± 1.1 AW047630 Ccrn4l U 2.3 1207 2.2 ± 0.4 2.4 ± 0.2 1.7 ± 0.6 2.1 ± 0.4 AI530403 Acaa1 U 2.3 592 1.7 ± 0.2 2.4 ± 0.8 2.1 ± 0.6 2.2 ± 0.6 AF064635 Hsd17b12 U 2.3 3127 2.3 ± 0.8 2.8 ± 0.8 2.0 ± 0.8 2.5 ± 0.8 AF036164 Serpinf1 U 2.4 455 2.2 ± 0.9 2.2 ± 0.7 2.5 ± 0.9 2.3 ± 0.8 K03235 Plf U 2.6 366 4.2 ± 2.9 3.0 ± 2.0 4.4 ± 3.2 3.8 ± 2.7 AI255972 4931406C07Rik U 3.5 220 7.7 ± 6.7 5.5 ± 5.2 5.9 ± 5.2 6.3 ± 5.4 AV361373 Pdc U 3.7 3.8 3.0 3.5 596 5.3 ± 3.7 5.3 ± 5.7 3.5 ± 4.2 4.9 ± 4.5 AI837130 Itpk1 U 2.5 2.1 1356 1.6 ± 0.5 2.0 ± 0.5 2.1 ± 0.7 2.0 ± 0.5 AA798624 Ero1l 3.2 1.9 4391 1.1 ± 0.7 1.8 ± 1.3 3.4 ± 3.2 2.5 ± 2.4 AW123751 2310056P07Rik 2.4 2.1 2200 1.3 ± 0.4 2.2 ± 0.4 2.3 ± 0.6 2.1 ± 0.6 Z12604 Mmp11 3.1 2.2 720 1.7 ± 0.1 1.5 ± 0.1 2.7 ± 0.8 2.1 ± 0.7 M31658 Ghrh 3.0 2.3 891 1.5 ± 0.3 1.9 ± 0.2 2.6 ± 0.9 2.1 ± 0.6 X51829 Myd116 4.4 2.7 558 1.8 ± 0.5 1.8 ± 0.5 4.2 ± 1.7 2.8 ± 1.5 AV298880 Rbm9 4.1 3.4 344 3.2 ± 1.0 2.2 ± 0.5 3.1 ± 2.3 3.0 ± 1.6 Y12577 Arl4 2.9 2.1 1342 1.7 ± 1.1 3.5 ± 3.4 2.3 ± 2.1 2.5 ± 2.5 U01310 U 3.5 2.1 1576 3.4 ± 0.3 1.5 ± 0.1 1.4 ± 0.5 2.0 ± 0.8 AF009605 Pck1 U 4.3 2.4 1574 4.5 ± 1.5 2.5 ± 0.9 1.1 ± 0.5 2.5 ± 1.6 X01756 -2.8 2.7 1024 2.6 ± 1.6 2.8 ± 0.5 2.1 ± 0.6 2.5 ± 0.9 AA823381 Ndufa5 1.9 6899 2.4 ± 0.8 2.2 ± 1.0 1.8 ± 0.8 2.1 ± 0.9 U15977 Facl2 2.0 2294 2.0 ± 0.6 2.4 ± 0.4 1.4 ± 0.4 2.0 ± 0.5 AW049373 2310016A09Rik 2.0 1197 1.8 ± 0.8 2.2 ± 1.0 1.8 ± 0.7 2.0 ± 0.8 AI844355 2310042G06Rik 2.1 1001 1.5 ± 0.4 2.3 ± 0.5 1.7 ± 0.5 1.9 ± 0.5 AF055638 Gadd45g 2.2 608 2.5 ± 1.1 2.5 ± 1.5 2.4 ± 1.5 2.5 ± 1.3 AV250694 -2.2 597 2.4 ± 1.1 2.4 ± 1.8 2.0 ± 1.6 2.5 ± 1.6 AV347674 -2.3 792 2.4 ± 0.7 2.2 ± 0.7 2.2 ± 1.8 2.3 ± 1.1 M35797 Acat2 2.3 898 2.6 ± 2.1 3.9 ± 3.4 1.9 ± 1.5 3.0 ± 2.5 AI839083 Pus1 2.3 576 3.3 ± 1.9 2.8 ± 2.3 3.6 ± 1.8 3.2 ± 1.9 AI255972 4931406C07Rik 2.4 747 2.0 ± 0.4 2.7 ± 0.8 2.0 ± 0.7 2.3 ± 0.7 AF109905 -3.1 284 3.6 ± 1.5 3.5 ± 2.0 1.7 ± 1.1 3.0 ± 1.7 AA764261 Pim1 2.4 892 1.5 ± 0.4 1.6 ± 0.5 2.2 ± 0.8 1.9 ± 0.6 AF003348 Npc1 2.5 1413 1.1 ± 0.2 1.1 ± 0.3 2.3 ± 0.8 1.6 ± 0.8 K02236 Mt2 2.5 8065 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.6 1.5 ± 0.8 AW120614 -2.8 10346 1.1 ± 0.2 1.5 ± 0.2 2.6 ± 0.9 1.9 ± 0.8 Table 1 . Continued Probe Gene SAM Cyber-T VAMPIRE Statistics P R T X P R T X P R T X C P R T X X67083 Ddit3 2.9 2908 1.3 ± 0.3 1.3 ± 0.6 2.9 ± 1.2 1.9 ± 1.1 X56824 Hmox1 2.4 1892 2.5 ± 0.8 1.4 ± 0.4 1.9 ± 1.0 2.0 ± 0.8 AI837948 E130012A19Rik
3.5 378 3.4 ± 1.2 1.0 ± 0.4 0.7 ± 0.4 1.5 ± 1.3
The numbers listed under VAMPIRE are the fold-ratios between the means of the posteriors. Only fold-ratios for significant changes are shown. The columns on the right show several standard statistics for this dataset. The column labeled 'C' lists the mean average-difference scores from MAS 5.0 of DMSO-treated 3T3-L1s. The rightmost columns show the mean and standard error of fold-change, computed from all pairwise combinations of TZD-treated to control measurements. Legend: C, vehicle control; P, pioglitazone; R, rosiglitazone; T, troglitazone; and X, pooled TZD treatments.
or gene regulation by Gene Ontology. These included phosphoenolpyruvate carboxykinase 1 (Pck1), acetyl-CoA acetyltransferase 2 (Acat2), fatty acid CoA ligase 2 (Facl2) and growth arrest and DNA-damage-inducible 45 gamma (Gadd45g). At the same time, of the 24 genes that only SAM considered statistically significant, only one had known function in metabolism or gene regulation. This sole gene was Cbp/p300-interacting transactivator 2 (Cited2). Cyber-T detected very few additional genes in pooled TZD data, and none of these had related functions. The identities of the remaining genes can be found in Tables 1-3 . While the differences in numbers of Gene Ontology annotations are probably not statistically significant, these results do demonstrate that when the number of replicates is large, and the desired false positive rate is low (0.05), all of these methods also show a similar level of specificity. In most microarray experiments, investigators rarely use ample replication to assess gene expression at the greatest level of precision. In most cases, only two or three replicates of each treatment condition are performed. Similarly, we compared individual TZD treatments with controls to observe the effect of this low level of replication. Neither SAM nor Cyber-T was able to reproduce a similar set of differentially regulated genes when analyzing unpooled, individually treated data. In both cases, only a handful of genes were found for each TZD treatment, and there was minimal overlap between the 'significant' genes. This contradicts our intuitive understanding that PPAR-γ ligands should influence the expression of the same set of genes. In contrast, VAMPIRE found an average of 50 differentially expressed array features in each of the individual treatments. These sets had substantial overlap with each other, as well as with the pooled TZD analysis, sharing a total of 23 genes (Fig. 8) . Furthermore, of the 24 genes that were selected by all 3 statistical methods on the pooled data, 12 of these were also found by VAMPIRE to be 'significant changes' in all 3 individual treatments. It is therefore apparent that even when the number of experimental replicates is low, our method retains ample sensitivity and specificity, which is typically lost by other approaches.
DISCUSSION
The detection of differentially expressed genes is a common starting point for the interpretation of microarray data. At high replicate numbers, VAMPIRE, Cyber-T and SAM all perform similarly. The results suggest that our global model of variance is suitable for understanding the degree of experimental variability for each feature on the array. At low replicate numbers, our model, adapted from Rocke and Durbin (2001) , takes advantage of a known relationship between variance and gene expression level to extrapolate an estimate of variance beyond what is available in the few experimental replicates. Without using such a model, the measurement variability is essentially left undetermined, and a feature-specific test can identify very few significant expression changes. Therefore, both SAM and Cyber-T are only able to identify very few 'statistically significant' genes from smaller datasets.
Although it is still ideal to collect a greater number of replicates for an optimally controlled microarray experiment, our method attempts to maximize the value of the available dataset. In comparison with current approaches, VAMPIRE appears to be much more sensitive at low replicate numbers for identifying these changes while preserving a considerable level of specificity. In addition, the relationships between traditional fold-change thresholds, expression-level cutoffs and levels of statistical significance have not previously been wellunderstood. The correspondence between our method and fold-change methods can now be qualitatively understood by examining 'significant' fold-changes at each expression level. At very high expression levels, the results of a 2-fold cutoff are very similar to results from VAMPIRE. At low-expression levels however, where features are typically removed in the fold-approach by a minimum-expression cutoff, VAMPIRE detects significance by implicitly adjusting the fold-change threshold. The statistical framework used in our method can clearly serve as a basis for quantitatively understanding traditional ideas of microarray analysis.
The empirical methods that we employ in our modeling procedure may be sophisticated, but they are grounded in conceptually simple ideas. VAMPIRE uses various estimation techniques to obtain robust parameter estimates directly from microarray data, and uses the observed data to narrow the posterior to a normal distribution. The parameters of the variance model are computed by 'fitting' the MSDs, while accounting for the uncertainty involved in using the sample mean as a surrogate for the true expression mean. To obtain optimal estimates, our method takes advantage of commonly available computational power by applying MCMC simulation. The prior likelihood density can also be readily understood, although a familiarity with the Bayesian concept of prior and posterior likelihoods is necessary. When a prior density based on prior knowledge is not available, we rely on the distribution of gene expression across the array as a prior for the 'true mean' expression. When a greater number of features exhibit a given expression level, the prior probability at that expression level increases. Based on this concept, an estimate for the prior parameter, λ, is determined by employing an assortment of computational methods.
Besides its utility for inference in differential gene expression, the parameter estimates can provide additional information about the nature of the data we collect. In the case of the two-component variance model, the expression-dependent variance, A, and expression-independent variance, B, provide insight into the magnitude of variance at each level of gene expression. In our 3T3-L1 adipocyte data, we observed a relatively consistent set of parameter estimates, despite varying treatment conditions. This suggests that the sources of variance are relatively consistent across our experiments. On the other hand, if substantially different estimates are obtained for two similarly treated experiments, this may be a sign that there are inconsistencies in experimental procedures, or sources of uncontrolled variability. Furthermore, if the variance estimates are reliably different despite rigorous controls, then this suggests that the biological variability may be significantly different due to the treatments themselves.
The current model adapted into VAMPIRE accounts for two classes of variance in a global model, but can be extended to provide more detailed modeling of feature-specific variability. While there are undoubtedly other components of measurement variance that are dependent on each individual gene, it is not immediately clear what the corresponding relationships are. For example, it is possible that the variance may be dependent on the length or the nucleotides used in the probes for each feature. If such a relationship can be characterized, this information can then be incorporated into an improved model to obtain improved variance estimates. As with any model however, increasing refinement will also increase the number of unknown parameters, which become increasingly vague without additional sources of data. Because of this, a more refined model may or may not show increased predictive ability.
A number of Bayesian models have recently been described in the literature (Smyth, 2003) , which have further developed the approach taken by Baldi and Long (2001) . The empirical Bayes method devised by Smyth relies on array data to stably estimate the hyperparameters of a hierarchical model, which explicitly incorporates a linear model to describe the relationships between gene expression in different treatment conditions. Tests may then be performed on the 'contrast estimators' to determine whether observed expression changes are statistically significant. The moderated t-statistic used by Smyth is conceptually equivalent to the statistic Z i that we describe here. We believe that the global variance approach that we apply is likely to be more robust when the number of replicate measurements is low, for the same reasons that we have described previously. However, it is not clear whether this continues to be the case when large numbers of array replicates are available, and the sample variances become more accurate estimators of feature-specific variability.
The power of microarray analysis presumably lies far beyond that of determining differential-expression alone. These snapshots of gene expression can be interpreted across a variety of experimental conditions by a third tier of array analysis, which often involves a clustering approach. Current clustering methods commonly rely on deterministic foldchanges of gene expression for computing 'distances' between expression patterns of various genes. These methods are inherently limited by the same problems that limit a foldchange approach for detecting differentially expressed genes. The experimental variability of low-expression genes is large enough that large fold-changes may not represent true changes in gene regulation. It is therefore essential to incorporate an estimate of variability into clustering, and adapt a stochastic interpretation of a fold-change. For clustering methods that rely on fold-changes, we can apply the posterior density of the fold-change, which our model predicts is a Cauchy density. In place of a deterministic distance metric, we can instead apply the average distance between the expression patterns of each pair of genes, integrating over the likelihood densities. This 'average distance' metric still satisfies necessary requirements for a mathematical concept of distance: it is symmetric, positive definite with equality when the distance between a profile and itself is computed, and obeys the triangle inequality (although there may be multiple expression patterns that have zero-distance between them). If an absolute measure of gene expression is desired for clustering instead of a foldchange measure, the corresponding posterior density is even more convenient; it is normal. Again, an 'average distance' metric can be applied. The use of these posterior densities and a stochastic concept for measurements of gene expression should improve the reliability of clustering methods, and more generally, enhance the knowledge that we harvest from our microarray experiments. 
and from this, we derive the following heuristic
where γ is the maximum acceptable fractional error in the log-transformed variance.
Boundaries between expression regions
The variance model can be written as
where A is the expression-dependent and B is the expressionindependent variance. Defining ρ as the maximal accepted fractional change in variance, then all µ that satisfy the inequality
are included in the first expression region. The upper bound for this region is therefore
Successive regions can be iteratively found by computing the incremental change in variance over the previous regional boundary. Each region includes all µ that satisfy
Solving for the boundary gives 
A similar procedure can easily be performed to determine the boundaries of each log-transformed expression region.
Comments on the posterior shift and λ i
In order to reduce computational time, λ is only estimated by MCMC at the mean of each non-overlapping 'expression region'. Given that each feature on the array should have its own local prior, there are a number of ways to decide what value of λ i to use. The simplest method is to use the same λ i for all features whose sample means lie within a given region. This requires very little additional computation, but could potentially give inaccurate results because of discontinuities between regions. One alternative is to approximate values for λ i between computed locations by applying piecewise continuous and differentiable finite elements. We implement both methods in our analysis.
While it is probably effective to take the maximumlikelihood λ i as a point estimate, it is only marginally more difficult to apply the entire simulated likelihood density. The posterior density of µ i is normal under our model, and the linear combination of normal variates is also normal. In addition, the same linear combination gives us the mean of this combined density. Instead, if we choose the mean of posterior estimate, we effectively integrate the posteriors with respect to the likelihood of each prior.
Upper limit on MSD
The mean square deviation is computed as
or alternatively,
Maximizing MSD with respect tox,
It can be easily shown that when x j ≥ 0 for all j
Therefore, the upper bound is given by
where n is the number of replicate measurements.
